Ro, founded as Roman in 2017, is part of a growing crop of digital health companies aiming to capitalize on the soaring demand for GLP-1s by building programs and services for users on top of the medications
Thats why its important to work with a provider who can monitor your response and adjust your plan accordingly.
With rising global obesity rates, Foundayo could expand access, adherence, and long-term outcomes
However, whether GLP-1RA induces pancreatitis or pancreatic cancer by affecting the expression level of related genes in the pancreas or by regulating the secretion of pancreatic enzymes is still inconclusive
"If we didn't make any changes, we'd be looking at spending close to a billion dollars on these medications in 2026," McHugh added
doi:10.1016/S0140-6736(22)02033-5 Coskun T, Urva S, Roell WC, et al